INMB
INmune Bio Inc.
Biotechnology · Healthcare · United States
1.45
close · 2026-10-30
value
12
cheaper than peers12
quality
40
stronger fundamentals40
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.97× | 59 |
| earnings yield, 3 years ago | -104.8% | 38 |
| cash flow yield, 2 years ago | -26.7% | 36 |
| earnings yield, 2 years ago | -115.2% | 30 |
| cash flow yield, latest year | -52.6% | 23 |
| cash flow yield, 3 years ago | -50.5% | 20 |
| cash flow yield, 1 year ago | -74.3% | 17 |
| earnings yield, latest year | -128.3% | 15 |
| earnings yield, 1 year ago | -145.5% | 15 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 6.9% | 45 |
| return on equity | -74.8% | 43 |
3 of 4 measures available
Facts
| market cap | $45M |
| free cash flow | -$10.0M |
| employees | 21 |
| first trade | 2019-02-04 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-19 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.86 | -2.11 | -1.67 | -1.52 |
| free cash flow | -$23.6M | -$33.4M | -$12.0M | -$22.7M |
| net income | -$45.9M | -$42.1M | -$30.0M | -$27.3M |
| revenue | $50,000 | $14,000 | $155,000 | $374,000 |
| unusual items | -$16.5M | $0 | not reported | not reported |